Aliz é Pharma to report Phase II trial results of AZP-531 to treat PWS

French-based biopharmaceutical company Aliz é Pharma will report results of its Phase II trial of AZP-531 to treat patients with Prader-Willi (PWS) syndrome.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news